Arca Biopharma Inc (NASDAQ:ABIO): The Atrial Fibrillation Treatment Application Accepted

0
482

Dallas, Texas 12/09/2013 (Financialstrend) – Arca Biopharma Inc (NASDAQ:ABIO) which is responsible for developing genetically-targeted therapies for cardiovascular diseases recently announced that their Atrial Fibrillation treatment application has been accepted the US FDA and is now active. As per the biopharma company they wish to evaluate Gencaro as a potential treatment for Atrial fibrillation under their Phase 2B/3 GENETIC-AF clinical trial and patients will be enrolled for the treatment in the first quarter of 2014. To add further the company also said that they have identified common genetic variations that can predict individual patient response to Gencaro.

Arca Biopharma Inc (NASDAQ:ABIO) also believes that the Gencaro has the potential to be the first genetically targeted therapy for the prevention of Atrial fibrillation.

What does the future has stored for this stock?

Arca Biopharma Inc (NASDAQ:ABIO) also believes that the clearance by the DSMB around 2016 will make them proceed towards the phase 3 portion of the entire study and after another 30 months the next lot of 420 patients will get enrolled and they will be in a better position to report their top-line results. As per the news the phase 2 of the study will seek enrollment at around 50-60 centers in the US and out of these 50-60 centers almost 30-50 centers will come online once the DSMB will review them in the mid 2016.

All these things might lead to overall acceleration of the enrollment which will lead them towards 2018 and if all goes well according to the pre-designed plan the ACRA will be in a better position to re-file the NDA on bucindolol during the first half of 2019. Then the regulatory decision will come by late 2019 and people can expect the potential launch in 2020. All this seems to be in the favor of the ACRA biopharma.

This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.